Supplemental Table 1 from Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial

Abstract
Cardiac treatment-emergent adverse events in the two trial groups